Teacher Retirement System of Texas Has $324,000 Stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Teacher Retirement System of Texas increased its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 5.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,098 shares of the biotechnology company’s stock after purchasing an additional 2,020 shares during the quarter. Teacher Retirement System of Texas’ holdings in Aurinia Pharmaceuticals were worth $324,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Intech Investment Management LLC bought a new stake in shares of Aurinia Pharmaceuticals during the third quarter worth approximately $262,000. Charles Schwab Investment Management Inc. grew its holdings in Aurinia Pharmaceuticals by 13.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock worth $5,454,000 after acquiring an additional 89,940 shares during the period. FMR LLC raised its position in shares of Aurinia Pharmaceuticals by 44.8% during the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock valued at $93,000 after acquiring an additional 3,919 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Aurinia Pharmaceuticals by 172.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 32,078 shares of the biotechnology company’s stock valued at $235,000 after acquiring an additional 20,324 shares during the last quarter. Finally, Verition Fund Management LLC lifted its stake in shares of Aurinia Pharmaceuticals by 209.0% in the 3rd quarter. Verition Fund Management LLC now owns 58,518 shares of the biotechnology company’s stock valued at $429,000 after purchasing an additional 39,583 shares during the period. Institutional investors and hedge funds own 36.83% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 27th.

Aurinia Pharmaceuticals Stock Up 0.1 %

AUPH stock opened at $8.05 on Wednesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The stock has a market capitalization of $1.11 billion, a P/E ratio of -53.66 and a beta of 1.26. Aurinia Pharmaceuticals Inc. has a fifty-two week low of $4.71 and a fifty-two week high of $10.67. The business has a 50-day moving average of $8.10 and a 200-day moving average of $8.07.

Insider Activity at Aurinia Pharmaceuticals

In related news, insider Greg Keenan sold 8,305 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $8.23, for a total transaction of $68,350.15. Following the completion of the transaction, the insider now directly owns 153,484 shares of the company’s stock, valued at approximately $1,263,173.32. This represents a 5.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Matthew Maxwell Donley sold 65,902 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $527,216.00. Following the transaction, the chief operating officer now owns 739,456 shares in the company, valued at approximately $5,915,648. The trade was a 8.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 343,898 shares of company stock valued at $2,753,094. Corporate insiders own 4.30% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.